Home AML Pfizer Study Evaluates Addition of Glasdegib in AML & High-Risk MDS Patients

Pfizer Study Evaluates Addition of Glasdegib in AML & High-Risk MDS Patients

248
0
Leukemia

A Pfizer-sponsored study recently generated clinical results. This was a study to evaluate PF-04449913 (an inhibitor of the Hedgehog pathway) in Acute Myeloid Leukemia and high-risk Myelodysplastic Syndrome in combination with standard agents used to treat these diseases. As reported in Nature, the addition of the Hedgehog pathway inhibitor glasdegib to low-dose cytarabine (LDAC) may benefit patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). These findings were reported in the journal Leukemia that that this combination therapy has a favorable benefit-risk ratio and may be a promising option for AML patients unsuitable for intensive chemotherapy.  The trial included over 80 sites with significant leadership from the University of Texas, MD Anderson Cancer Center in Houston. Led by Jorge E. Cortes, investigators

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.